BCM
PMVP icon

Bayesian Capital Management’s PMV Pharmaceuticals PMVP Stock Holding History

Bayesian Capital Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,200
Closed -$217K – 982
2022
Q3 		$217K Buy
18,200
+1,000
+6% +$14.4K 0.04% 509
2022
Q2 		$245K Buy
+17,200
New +$250K 0.05% 551

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Bayesian Capital Management's PMVP Position: Q4 2022 in Review

Bayesian Capital Management sold out of PMV Pharmaceuticals (PMVP) in Q4 2022, closing a stake of 18,200 shares — an estimated $217K sold.

Bayesian Capital Management first reported a position in PMVP in Q2 2022 and held it in 2 quarters. The position peaked at $245K in Q2 2022. 115 funds tracked by Wall St. Rank hold PMVP as of Q4 2022.

  • Bayesian Capital Management reported no remaining PMV Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 18,200 PMV Pharmaceuticals shares in Q4 2022, an estimated $217K.
  • Bayesian Capital Management first reported a position in PMV Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Bayesian Capital Management's PMV Pharmaceuticals position peaked at $245K in Q2 2022.
  • 115 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2022.

Based on Bayesian Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.